Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le lundi 3 février 2020
Doi : 10.1016/j.jaad.2019.05.099
accepted : 22 May 2019
Reproductive patterns and maternal and pregnancy outcomes in women with psoriasis—A population-based study

Mats Lambe, MD, PhD a, b, , Anna V. Bergstrom, MD c, Anna L.V. Johansson, PhD a, Caroline E. Weibull, PhD a, d
a Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 
b Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden 
c Dermatology Unit, Department of Medicine, University Hospital, Uppsala, Sweden 
d Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden 

Correspondence to: Mats Lambe, MD, PhD, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, 171 77 Stockholm, Sweden.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetPO Box 281Stockholm171 77Sweden

Data on pregnancy outcomes in women with psoriasis are conflicting.


We examined whether maternal psoriasis affects the risk of adverse maternal and pregnancy outcomes.


We used population-based data to compare reproductive patterns in women with and without psoriasis. Odds ratios (ORs) with 95% confidence intervals (CIs) for adverse outcomes were estimated with adjustments for maternal age, period of childbirth, smoking, and prepregnancy body mass index.


Compared with women without psoriasis, women with psoriasis were younger at first birth and had longer interpregnancy intervals but did not differ in final parity. Risk estimates in women with psoriasis were elevated for pregnancy hypertension (OR, 1.37; 95% CI, 1.19-1.58), premature rupture of membranes (OR, 1.15; 95% CI, 1.04-1.27), large for gestational age (OR, 1.11; 95% CI, 1.01-1.21), cleft palate (OR, 1.69; 95% CI, 1.07-2.66), and unspecified malformations (OR, 1.08; 95% CI, 1.01-1.16).


No information was available on lifestyle, disease severity, or type and duration of treatment. Small numbers hampered the assessment of rare outcomes.


Although there was no evidence that fertility is negatively affected, women with psoriasis were at an increased risk of several adverse maternal and pregnancy outcomes. Our findings add to a growing body of evidence that pregnancies in women with psoriasis need special monitoring.

The full text of this article is available in PDF format.

Key words : malformations, maternal outcomes, pregnancy outcomes, parity, psoriasis, register, Sweden

Abbreviations used : BMI, CI, ICD, ICD10 SE, MGR, MBR, OR

 Drs Weibull and Johansson contributed equally to this article.
 Funding sources: Supported by an Investigator Initiated Research Grant from Pfizer Inc. (IIR WS2059711) and the Karolinska Institutet Research Funds. The sponsors had no role in the study design, data collection, data analysis, data interpretation or writing of the report.
 Disclosure: Dr Lambe owns stocks in AstraZeneca and Pfizer Inc. Drs Bergstrom, Johansson, and Weibull have no conflicts of interest to declare.
 Reprints not available from the authors.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline